Last reviewed · How we verify
NCT04165525: CHEST
ConMed HelixAR™ ElectroSurgical Generator With Argon Beam Coagulation Technology Study
NA trial testing Ablation in Mastectomy; Lymphedema in 82 participants. Status unknown.
30 June 2022
Quick facts
| Lead sponsor | SurgiQuest, Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 26 May 2021 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ablation
Conditions studied
- Mastectomy; Lymphedema — all drugs for Mastectomy; Lymphedema →
Sponsor
SurgiQuest, Inc.
Who can join
Adults 18 to 80, female only, with Mastectomy; Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE HELIXAR ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION (CEC) FOR CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04165525
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ablation
Trials testing the same drug.
- NCT07521618 — One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation · NA · not yet recruiting
- NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
- NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting
- NCT06644430 — Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma · recruiting
- NCT06609850 — The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma · NA · recruiting
Other recruiting trials for Mastectomy; Lymphedema
Currently open trials in the same condition.
- NCT06914258 — Effects of Inhibition Compression Versus Scapular Mobilization Technique on Shoulder in Patients With Mastectomy · NA · active not recruiting
- NCT06574022 — Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks · Phase 4 · recruiting
- NCT05115799 — Effects of a Manual Therapy Program to Reduce the Evolution Time of Axillary Web Syndrome · NA · recruiting
- NCT04356235 — Examining and Comparing the Temporal Changes and Results of Cosmetic, Quality of Life and Patient Satisfaction Achieved · recruiting
- NCT04345081 — Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mast · recruiting
Other SurgiQuest, Inc. trials
Trials by the same sponsor.
- NCT07312006 — Comparison of AirSeal to DV5 Insufflation in Gastric Sleeve Procedures - The "CAT5-GS" Study · NA · not yet recruiting
- NCT07313930 — Gastrectomy at Low Pressure Trial - (GALPT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04165525 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SurgiQuest, Inc.
- Last refreshed: 9 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04165525.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing